Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients With Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy
Conditions
Interventions
Evinacumab
Matching placebo
+1 more
Locations
95
United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Office of Dr. John D Homan MD
Newport Beach, California, United States
Preventive Cardiology Inc
Boca Raton, Florida, United States
Care Research Center Inc
Doral, Florida, United States
Florida Lipid Institute
Winter Park, Florida, United States
St. Vincent Medical Group, Inc
Indianapolis, Indiana, United States
Start Date
November 10, 2017
Primary Completion Date
May 22, 2020
Completion Date
December 14, 2020
Last Updated
February 10, 2023
NCT07058077
NCT06555120
NCT06287177
NCT00353782
NCT06556745
NCT06314919
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions